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Antimicrobial activity of apple cider 
vinegar against Escherichia coli, 
Staphylococcus aureus and Candida 
albicans; downregulating cytokine 
and microbial protein expression
Darshna Yagnik, Vlad Serafin & Ajit J. Shah
The global escalation in antibiotic resistance cases means alternative antimicrobials are essential. The 
aim of this study was to investigate the antimicrobial capacity of apple cider vinegar (ACV) against E. 
coli, S. aureus and C. albicans. The minimum dilution of ACV required for growth inhibition varied for 
each microbial species. For C. albicans, a 1/2 ACV had the strongest effect, S. aureus, a 1/25 dilution 
ACV was required, whereas for E-coli cultures, a 1/50 ACV dilution was required (p < 0.05). Monocyte 
co-culture with microbes alongside ACV resulted in dose dependent downregulation of inflammatory 
cytokines (TNFα, IL-6). Results are expressed as percentage decreases in cytokine secretion comparing 
ACV treated with non-ACV treated monocytes cultured with E-coli (TNFα, 99.2%; IL-6, 98%), S. aureus 
(TNFα, 90%; IL-6, 83%) and C. albicans (TNFα, 83.3%; IL-6, 90.1%) respectively. Proteomic analyses 
of microbes demonstrated that ACV impaired cell integrity, organelles and protein expression. ACV 
treatment resulted in an absence in expression of DNA starvation protein, citrate synthase, isocitrate 
and malate dehydrogenases in E-coli; chaperone protein DNak and ftsz in S. aureus and pyruvate 
kinase, 6-phosphogluconate dehydrogenase, fructose bisphosphate were among the enzymes absent 
in C.albican cultures. The results demonstrate ACV has multiple antimicrobial potential with clinical 
therapeutic implications.
Antibiotic resistance is rapidly becoming a major worldwide problem. There has been a steady increase in 
the number of pathogens that show multiple drug resistance. In fact the World Health Organization predicts 
that infections involving antibiotic resistant pathogens will pose major patient care management issues in the 
future1.This will inevitably lead to an increase in hospital stays, cost, patient morbidity and mortality. In the 
immunocompromised and at risk patients severe microbial infections can result in sepsis. Sepsis can rapidly 
lead to systemic inflammation and organ failure2. In response to microbial invasion, the innate immune sys-
tem reacts by triggering tissue damage. Mononuclear cells recognize pathogens associated with molecular pat-
terns (PAMPs) present on the microbial surface. This results in intracellular signaling cascades which initiate 
pro-inflammatory cytokine and chemokine release into the blood circulation. Unchecked, the chemokines will 
continue to recruit more immune cells to the site of infection which release further pro-inflammatory cytokines 
enhancing inflammation in a continuous feedback loop3. Essentially, antibiotics are antimicrobials but can also 
act as immune modulators reducing the release of pro-inflammatory cytokines such as IL-1β, IL-6, TNFα, IL-8, 
and interferon-gamma (INF-gamma). Antibiotics can also affect mononuclear phagocytic function and modu-
late the activity of nuclear transcription factors such as NF-ĸB and activator proteins4–7. Microorganisms such as 
E-coli, S. aureus and C. albicans form part of the human microbiota. However pathogenic forms of these microbes 
have been implicated in blood or urinary tract infections, gastroenterititis, endocarditis, soft tissue infections and 
organ malfunction8–10.
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The anti-microbial agents used to treat gram negative infections such as β-lactams, fluroquinolones, sul-
famethaoxathoxazole and trimethroprin are becoming increasingly ineffective. Strains of S. aureus have emerged 
with reduced susceptibility to vancomycin and methicillin6,11,12. Furthermore, antibiotic action itself can be prob-
lematic in terms of cell membrane permeability, intracellular inactivation and the inability to reach intracellular 
structures in which organisms can hide. Alternative supplementation that can combat a plethora of microbes 
without concurrent side effects would be of significant healthcare interest as the discovery of effective new antibi-
otic has been slow but should be a global priority.
The Old Testament and Hippocrates reported on the use of ACV in combination with honey to combat infec-
tion and protect open skin wounds. Historically, vinegar has been produced and sold as a commercial commodity 
for over 5000 years. In fact up until the sixth century BC, the Babylonians were making vinegars for consumption 
as well as for use in healing13. Vinegar is the resultant product when ethyl alcohol is converted to acetic acid by 
Acetobacter. It can be produced by different methods and a variety of raw materials such as wine, malted barley, 
alcohol, fruits and cider14. ACV is produced from cider that has undergone acetous bioconversion and has rela-
tively low acidity (5% acetic acid). It also contains organic acids, flavonoids, polyphenols, vitamins and minerals15. 
ACV has been hailed as a supplement aiding weight loss, hyperlipademia, hypercholesterliaemia, nutritional 
support, antioxidant defence and lowering blood pressure. Utilising organic acids as nutritional supplements 
has been regarded as safe and can eliminate harmful intestinal bacteria16–18. The positive impact of dietary ACV 
supplementation has been highlighted in vivo. ACV decreased the serum lipid profile in mice fed a high choles-
terol diet over 28 days. Intragrastric ACV addition induced a protective effect against erythrocyte, kidney and 
liver oxidative injury as well as lowering cholesterol levels16. ACV also decreased blood triglyceride and very low 
density lipoprotein levels in rats which had induced cholesterol induced hepatic steatosis18. Despite the known 
health benefits of dietary organic acid supplementation, to the best of our knowledge the direct effect of ACV on 
microbes and mononuclear leucocytes has not been examined. The aim of the present study was to investigate the 
antimicrobial activity of ACV on microbes and associated inflammatory pathways.
Results
The antibacterial and antifungal activity of ACV against E. coli, S. aureus and C. albicans. In 
order to determine the anti-microbial activity of ACV, E. coli, S. aureus and C. albicans were directly cultured 
with different concentrations of ACV. Figure 1 represents the experimental results. The minimum dose required 
to restrict growth for C. albicans was neat, undiluted ACV (5% acidity), for S. aureus it was a 1/2 dilution (2.5% 
acidity) and for E-coli, growth was restricted at a significantly lower dilution of 1/50 (equivalent to 0.1% acidity). 
We also measured the equivalent zones of inhibition (in mm) for each of the microbes at varying dilutions of 
ACV which is depicted in the photographs of the culture plates (Fig. 2). To translate the MIC into supplementary 
Figure 1. Effect of varying concentrations of ACV on microbial growth after incubation at 37 °C for 24 h. (a) 
S. aureus; (b) C. albicans, (c) E-coli (d) E-coli. ACV was either applied neat or diluted 1:2 or 1:10 v/v in distilled 
water. Zones of microbial growth inhibition are indicated by clear zones and vary with ACV dilutions for each 
microbe. Photographs were taken using a 20 Mega pixel Samsung camera.
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tablet dosages required, we tested concentration ranges from 400 µg/ml in doubling microdilutions to the lowest 
of 3.1 µg/ml against each microbe. The MIC for ACV tablets at which no growth was visible was 62 µg/ml for E. 
coli; 125 µg/ml for S. aureus and 250 µg/ml for C. albicans respectively. Both sets of results were also confirmed 
further by microdilution. We used the Braggs ACV for all future experiments at the minimum inhibitory dilution 
required for each organism.
Downregulation of pro-inflammatory cytokine secretion by ACV in monocytes exposed to 
microbes. The microbes utilised in our study have been extensively studied and are known to cause inflam-
mation through their capacity to stimulate the leucocyte pro-inflammatory cytokine cascades19,20. Hence, we 
proceeded to measure mononuclear derived TNF-α and IL-6 cytokines as indicators of inflammation which are 
also the markers of choice for clinical diagnosis of septic infections21.
Figure 3 depicts the effects of a dose dependent reduction in TNFα and IL-6 release from monocytes which 
have been co-cultured with ACV, together with either C. albicans, E-coli or S. aureus for 24 h.
Consistent with the microbial growth inhibition data depicted in Fig. 2, the effect of ACV at the minimum 
inhibitory concentration of 1/50 resulted in a significant reduction in monocyte derived TNFα (p = 0.008) and 
IL-6 release (P = 0.001) in monocytes cultured with E-coli. For S. aureus the minimum inhibitory concentration 
for ACV was found to be 1/10 in terms of reduction of TNFα (p = 0.011) and IL-6 (p = 0.03). For C.albicans the 
minimum inhibitory dilution was lower at 1/2 dilution, for TNFα (p = 0.003) and IL-6 (p = 0.008). It was imper-
ative to ascertain whether the monocytes were alive during inoculation with the various microbes especially 
after incubation for 24 h at 37 °C. We added Trypan blue directly to monocytes which had been co-cultured with 
microbes after 2, 6 and 24 h. Light microscopy revealed that greater than 90% of cells were alive after 24 h in all 
co-cultures as demonstrated in (Fig. 4a,b,c) which represents the light microscopic images of monocytes and the 
microbes in co-cultures.
Upregulation of phagocytic capacity. We also investigated whether ACV could have an effect on the 
phagocytic function of monocytes alone and also after a 4 h exposure to microbes with or without ACV treat-
ment. A 14.2, 13.7 and 20.4% increase in monocyte phagocytic capacity was observed after E. coli, S. aureus and 
C. albicans co-culture with ACV respectively and in comparison to the resting unstimulated monocytes. Results 
are expressed as the mean and SD of 3 similar experiments (Table 1). This suggests that ACV can increase phago-
cytic potential in monocytes which is significant as microbial phagocytosis is a key effector function of innate 
immunity22.
Figure 2. Inhibition of microbe growth by ACV after incubation for 24 h at 37 °C. (a) E-coli; (b) S. aureus (c) 
C. albicans. Zone of inhibition was measured in mm. These experiments represent data from three repeats. 
EC = E-coli, SA = S. aureus, CA = C. albicans, ACV = Apple cider vinegar.
www.nature.com/scientificreports/
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Proteomic results of E. coli, S. aureus and C. albicans after exposure to ACV. The bottom-up 
proteomic study of ACV treated E-coli cultures revealed the absence in detection of key enzymes; citrate synthase, 
isocitrate dehydrogenase, deoxyribose–phosphate idolase, malate dehydrogenase, aminomethyltransferase and 
formate acetyltransferasesuccinyl-CoA ligase (Table 2). An absence in acyl carrier protein, DNA protein includ-
ing DNA protection during starvation protein, integration host factor subunit alpha and ribosome associated 
inhibitor A was evident. Following ACV treatment S. aureus cultures failed to express 50 s ribosomal proteins L2, 
L15, L23, L24, enzymes; alcohol dehydrogenase, catalase, formate acetyltransferase, L-lactate dehydrogenase-2, 
ornithine aminotransferase and serine hydroxymethyl transferase (Table 3). Cell division protein ftsZ and 
chaperone protein Dnak were also not detected. However an important pentose phosphate pathway enzyme: 
6 phosphogluconate dehydrogenase decarboxylating was displayed. Table 4 demonstrates that key enzymes 
required for glycolysis and candida immunogenicity were undetected after 24 h of exposure to ACV in C. albi-
cans. These incorporated fructose bisphosphate aldolase, phosphogluconate dehydrogenase, pyruvate kinase and 
peptidyl-propyl cis-trans isomerase.
Discussion
ACV has multiple antimicrobial properties on different microbial species, affecting microbe growth, suppressing 
mononuclear cytokine and phagocytic responses. The tandem mass spectroscopy results are in cohesion with 
Figure 3. Effect of ACV on pro-inflammatory cytokine secretion from human monocytes infected with (a) 
E-coli; (b) C. albicans and (c) S. aureus after incubation for 24 h at 37 °C. ACV was added at dilutions of 1/10, 
1/25, 1/50, 1/100 or 1/1000. EC = E-coli, SA = S. aureus, CA = C. albicans. The minimum inhibitory dilution 
of ACV required for significant pro-inflammatory downregulation varied with each microbe. For TNFα, a 
1/50 ACV minimum inhibitory dilution was required for EC, p = 0.0008; 1/10 for SA, p = 0.01; 1/2 for CA, 
p = 0.0003 respectively. For IL-6, 1/50 ACV dilution was required for EC, p = 0.0008; 1/10 for SA, p = 0.03; 
1/2 for CA, p = 0.008 respectively. Results represented are mean +/− SD of 3 experiments. We used student’s 
paired t-tests for statistical evaluation (Excel 2017) with statistical significance taken when p < 0.05. EC = E-coli, 
SA = S. aureus, CA = C. albicans, ACV = Apple cider vinegar.
www.nature.com/scientificreports/
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these observations. The microbes underwent significant impairment following ACV addition which damaged cell 
integrity, structural and metabolic proteins as well as nuclear material. Indeed the enzymes citrate synthase, isoc-
itrate dehydrogenase, malate dehydrogenase, aminomethyltransferase and formate acetyltransferasesuccinyl-CoA 
ligase are crucial for E-coli growth, gene regulation and central, intracellular carbon metabolism. An absence of 
these enzymes would affect glycolytic, tricarboxylic acid cycle, pentose phosphate, glycoxlate shunt and oxidative 
phosphorylation pathways in E. coli23. Furthermore, the absence of DNA binding protein from starved cells, is 
significant as it protects E-coli and functions to control gene regulation during cell starvation24. With respect to 
other proteins, we observed the presence of ribosomal proteins (L1, L6 and 30 s ribosomal proteins (S1, S4, S6, 
Figure 4. (a–c) Photos of monocytes in co-culture with microbes. Monocytes were cultured with the microbes 
and ACV. Trypan blue addition indicated over 95% viability. Red arrows indicate microbes and the blue arrow 
shows monocytes in Fig. 4a which are not visible in Fig. 4b and c since they have been covered by the microbes. 
Photographs were taken after 24 h incubation at 37 °C under × 100 magnification using a light microscope 
indicated over 90% viability with monocytes at 2, 4, 6 and 24 h of co-culture (24 h photos shown). A = C. 
albicans, B = E-coli and C = S. aureus respectively.
www.nature.com/scientificreports/
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Monocyte co-culture 
conditions
Monocyte phagocytic capacity 
expressed as % change increase in side 
scatter. (mean ± SD)
Medium 6.1 ± 1.4
E-coli 9.0 ± 2.4
S. aureus 22.3 ± 2.2
C albicans 31.9 ± 2.4
E-coli + ACV 23.2 ± 3.7
S. aureus + ACV 36.0 ± 5.2
C albicans + ACV 52.3 ± 4.1
Table 1. Effect of ACV on human monocyte phagocytic capacity. In vitro differentiated monocytes were 
incubated with microbes for 4 h at 37 °C. Cells cultured with microbes with or without ACV were washed and 
processed for detection on the Beckton Dickinson flow cytometer. An analysis of changes in regional gated 
profiles and % shift in side scatter was measured. Data is presented as mean ± SD of 3 similar experiments.
Protein Name
Mass 
(Da)
Control E-coli 
culture
ACV Treated 
E-coli culture
30S ribosomal protein S1 — *
30S ribosomal protein S11 13950 *
30S ribosomal protein S4 23512 *
30S ribosomal protein S6 15177 *
30S ribosomal protein S7 17593 *
30S ribosomal protein S8 14175 *
50S ribosomal protein 14923 * *
50S ribosomal protein L1 24714 *
50S ribosomal protein L17 14413 * *
50S ribosomal protein L2 29956 *
50S ribosomal protein L6 18949 *
60 kDa chaperonin 57464 * *
Acyl carrier protein 8693 *
Aminomethyltransferase 40235 *
Autonomous glycyl radical cofactor — *
Citrate synthase 48383 *
Cytidine deaminase 31805 *
Deoxyribose-phosphate aldolase 27958 *
DNA protection during starvation protein 18684 *
DNA-binding protein H-NS 15587 *
DNA-binding protein HU-alpha 9529 *
DNA-binding protein HU-beta 9220 *
Elongation factor Tu 1 43427 * *
Enolase 45683 * *
Formate acetyltransferase 1 85588 *
Glutamate/aspartate periplasmic-binding protein 33513 *
Glyceraldehyde-3-phosphate dehydrogenase 35681 * *
Integration host factor subunit alpha 11347 *
Isocitrate dehydrogenase [NADP] 46070 *
Major outer membrane lipoprotein Lpp 8375 *
Malate dehydrogenase 32488 *
Outer membrane protein A 37292 * *
Ribosome-associated inhibitor A 12777 *
Succinate dehydrogenase flavoprotein subunit 65008 * *
Succinyl-CoA ligase [ADP-forming] subunit beta 42244 *
Transaldolase B 35368 *
Uridine phosphorylase 27313 * *
Table 2. List of E-coli proteins identified following ACV treatment. E-coli were cultured with 1/50 dilution of 
ACV or alone in broth for 24 hours at 37 °C in a shaking incubator. After which mass spectroscopy analysis 
was carried out. The “*” indicates the presence of protein whilst the blank region denotes no detection of that 
particular protein.
www.nature.com/scientificreports/
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S7, S8, S11) in ACV treated E. coli compared to control E. coli. These are mostly RNA binding proteins hence 
their presence could have been due to partial disintegration of 50 s and 30 s ribosomal breakdown whereas these 
subunits might remain intact in untreated E. coli cultures. The absence of ribosome associated inhibitor A could 
Protein name
Mass 
(Da)
Control 
S. aureus 
culture
ACV- 
Treated 
S. aureus 
culture
30S ribosomal protein S1 43250 * *
30S ribosomal protein S12 15334 *
30S ribosomal protein S2 29133 *
30S ribosomal protein S3 24085 * *
30S ribosomal protein S4 22999 *
30S ribosomal protein S5 17732 *
30S ribosomal protein S6 11588 *
30S ribosomal protein S7 17783 * *
30S ribosomal protein S8 14822 *
50S ribosomal protein L1 24693 *
50S ribosomal protein L13 16323 * *
50S ribosomal protein L14 13241 * *
50S ribosomal protein L15 15587 *
50S ribosomal protein L2 30194 *
50S ribosomal protein L21 11326 * *
50S ribosomal protein L23 10599 *
50S ribosomal protein L24 11529 *
50S ribosomal protein L25 23773 * *
50S ribosomal protein L29 8085 *
50S ribosomal protein L4 22451 * *
50S ribosomal protein L6 19774 *
6-phosphogluconate 
dehydrogenase, decarboxylating 51941 *
Alcohol dehydrogenase 36424 *
Arginine deiminase 47113 * *
Bacterial non-heme ferritin 23773 * *
Catalase 58457 *
Cell division protein FtsZ 41012 *
Chaperone protein DnaK 66338 *
DNA-binding protein HU 9620 * *
Elongation factor Tu 43134 * *
Enolase 47145 * *
ESAT-6 secretion system 
extracellular protein A 11029 *
Formate acetyltransferase 85264 *
Fructose-bisphosphate aldolase 
class 1 32907 *
Isocitrate dehydrogenase [NADP] 46451 *
L-lactate dehydrogenase 2 34468 *
Ornithine aminotransferase 2 43675 *
Ornithine carbamoyltransferase, 
catabolic 37853 * *
Probable malate:quinone 
oxidoreductase 56135 * *
Putative universal stress protein 
SA1532 18521 * *
Pyruvate dehydrogenase E1 
component subunit beta 35194 * *
Serine hydroxymethyltransferase 45384 *
Table 3. List of S. aureus proteins identified following ACV treatment. S. aureus were cultured with 1/10 
dilution of ACV or alone in broth for 24 hours at 37 °C in a shaking incubator. After which mass spectroscopy 
analysis was carried out. The “*” indicates the presence of protein whilst the blank region denotes no detection 
of that particular protein.
www.nature.com/scientificreports/
8ScieNTific RepoRTS |  (2018) 8:1732  | DOI:10.1038/s41598-017-18618-x
interrupt E. coli growth cycles as it serves to minimise translational errors25. Collectively these results support 
the cytotoxic effects of ACV we observed on E-coli. ACV treated S. aureus cultures did not express the chap-
erone protein Dnak and the cell division protein ftsz. This is significant as previous studies have shown that a 
non-functional DnaK system can cause a reduced tolerance to heat, oxidative, antibiotic stresses and lowered 
carotenoid production26. There was also an absence of gateway enzymes involved in multiple pathways such as 
ornithine aminotransferase27. 6 phosphogluconate dehydrogenase decarboxylating was expressed which is not 
surprising as it plays a critical role in protecting cells from oxidative stress28. The effect of ACV on C.albican pro-
tein moieties was less dramatic, nevertheless we did detect the absence of key enzymes which are fundamental in 
maintaining cell integrity and biosynthetic pathways29.
There could be a strong possibility that ACV acts like other anti-pathogenic compounds in diverting mono-
cyte responses through toll receptor signalling pathways. There is evidence that E-coli in particular can induce 
a typical M1 monocyte profile through mechanisms involving NF-kB activation. This results in upregulation of 
inflammatory cytokines TNF-α and PI3 kinase stimulation30. The in vitro M1 monocyte phenotype is also prom-
inent in severe sepsis. This was shown in a study using baboons where a substantial mortality rate correlated with 
high serum levels of TNFα and IL-6 following induced sepsis infection31. Unchecked high levels of circulating 
M1 cytokines can rapidly lead to cardiac arrest and death hence any factor capable of lowering pro-inflammatory 
cytokine concentrations is essential in therapy32. It has been reported that ACV consists of acetic acid, flavo-
noids such as gallic acid, tyrosol catechin, epicatechin, benzoic acid, vaninilin, caftaric acid, coutaric acid, caf-
feic acid, acid and ferrulic acid These constituents have been reported to affect immune defence and oxidative 
responses18,33.
Furthermore, the mechanism of ACV activity could be attributed in part to the apple polyphenol content. Yang 
et al. (2010) reported on the cellular protective effects of apple polyphenols on induced liver damage whereby 
histopathological tissue destruction was limited and liver activity maintained in mice that received the polyphe-
nols34. The mechanisms involved were free radical scavenger action, lipid peroxidation modulation and the anti-
oxidant upregulation capacity of ACV. Interestingly, a study by Denis et al. demonstrated the anti-inflammatory 
potential of apple phenols on gastrointestinal cell inflammation which involved downregulation of TNF and IL-6 
cytokines35. Another means of action could involve the acetic acid component of ACV which is able to reduce 
the cell hydrogen potential hence could potentially facilitate diffusion across the plasma membrane of microbes. 
Furthermore, there is evidence that organic acids can alter immune responses by binding to GPR3, a G pro-
tein coupled receptor which is mostly expressed on inflammatory leukocytes36. Also, an investigation reported 
on upregulated blood and plasma antioxidant enzyme release after apple consumption which would encourage 
immune protection16.
The positive benefits of dietary ACV supplementation have been highlighted in vivo. ACV decreased the 
serum lipid profile in mice fed a high cholesterol diet over 28 days. Intragastric ACV addition induced a pro-
tective effect against erythrocyte, kidney and liver oxidative injury as well as lowering cholesterol levels18. ACV 
Protein name
Mass 
(Da)
Control 
C.albicans 
culture
ACV- Treated 
C.albicans culture
40S ribosomal protein S1 29083 * *
6-phosphogluconate dehydrogenase 71270 *
Alcohol dehydrogenase 1 37255 * *
Elongation factor 1-alpha 1 50436 * *
Elongation factor 2 93865 * *
Enolase 1 47202 * *
Fructose-bisphosphate aldolase 39362 *
Glucose-6-phosphate isomerase 61148 *
Glyceraldehyde-3-phosphate dehydrogenase 35925 * *
Heat shock protein SSA1 70452 * *
Mitochondrial outer membrane protein porin 29748 *
Peptidyl-prolyl cis-trans isomerase 17678 *
Phosphoglycerate kinase 45266 * *
Phosphoglycerate mutase 27437 * *
Plasma membrane ATPase 1 98083 * *
Pyruvate decarboxylase 62744 * *
Pyruvate kinase 55752 *
Small heat shock protein 21 21482 * *
Triosephosphate isomerase 26880 * *
White colony protein WHS11 6991 *
Table 4. List of C. albicans proteins identified following ACV treatment. C. albicans were cultured with 1/2 
dilution of ACV or alone in broth for 24 hours at 37 °C in a shaking incubator. After which mass spectroscopy 
analysis was carried out. The “*” indicates the presence of protein whilst the blank region denotes no detection 
of that particular protein.
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also decreased blood triglyceride and very low density lipoprotein levels in rats which had induced cholesterol 
induced hepatic steatosis33. In an infection induced model of denture stomatitis, ACV addition resulted in 
anti-fungal activity against Candida Spp which was comparable to nystatin in terms of reducing microbial adher-
ence and destruction37.
Severe infections, autoimmunity or transplantation can inevitably lead to ineffective immunity in patients. 
An analysis of macrophages from Crohn’s disease patients revealed that they had defective responses to E-coli 
due to Crohn’s related systemic immunosuppression38. A recent report showed that co-administration of ACV 
with L-casei boosted systemic and mucosal immune responses, antioxidant enzyme and growth genes in fish39. 
Equally, perhaps additive dietary supplementation with ACV could be of benefit in acute infections, autoimmune 
induced immune dysregulation or antibiotic redundancy in humans. Future studies would establish whether 
ACV could be used as a potential therapeutic, In vivo models of infection could be induced by infusing microbes 
systemically into mice followed by treatment with or without intraperitoneal ACV. Intragastric ACV has been fed 
to animals used as models of obesity and infection in the past18,37,39. ACV efficacy could be evaluated by meas-
uring microbial burden, serum cytokine levels, leukocyte counts and tissue pathology. Side effects could include 
acid reflux, nausea or delayed digestion as ACV has a pH of 4.2. However, the acidity could be neutralised by the 
addition of sodium bicarbonate to preparations. The results of this study could have clinical implications as ACV 
could be used as an additive component of an antimicrobial therapeutic regimen especially in immunocompro-
mised patients presenting with infections of the aforementioned microbes.
We conclude that ACV can have multiple antimicrobial effects directly on E-coli, S. aureus and C. albicans. 
ACV addition can also decrease induced inflammatory cytokine release during mononuclear leukocyte infection 
and increases monocyte phagocytic capacity. Mechanisms include alteration of the microbial protein physiology 
destroying structural pathogenic proteins and metabolic enzymes. Collectively our results highlight the potent 
antimicrobial and therefore beneficial actions of ACV. This preliminary study encourages further work on dietary 
ACV supplementation investigating its antimicrobial role and the constituents which could be responsible for 
this activity.
Materials and Methods
Chemical reagents, microorganisms, media and culture conditions. A selection of microbial spec-
imens which represented a typical gram positive, a gram negative and a yeast species were chosen for initial 
investigation. Microbial strains: E-coli strain NCTC 10418 and S. aureus strains NCTC 6571 were purchased from 
Health Protection Agency (Colindale, U.K.). C. albicans strain 90828 was purchased from the American Type 
Culture Collection (LGC Promochem).
Reagents. Dulbecco’s modified media, dimethyl-ethyl-sulphonyl-oxide, HANKS balanced salt solution, his-
topaque, ethanol, phosphate buffered saline, paraformaldehyde, acetone, dithiothreitol, iodoacetamide, trypsin 
from porcine pancreas of proteomics grade, formic acid, acetonitrile, HPLC-grade water, methanol and Whatman 
Mini-UniPrep syringeless filter devices (pore size 0.45 µm) were purchased from Sigma Aldrich (Poole, U.K.). 
TNF-alpha, interleukin-6 (IL-6) enzyme linked immunosorbent assays (ELISA’s) were purchased from Research 
and Development Systems (Abingdon, U.K.). Mueller hinton agar was purchased from Oxoid, UK. Braag’s 
Apple Cider Vinegar and apple cider vinegar tablets (500 mg, Troo healthcare) were purchased from commercial 
sources.
Inoculum preparation and measurement of anti-microbial activity of ACV. Cultures of E. coli and 
S. aureus were grown in nutrient media whereas C. albicans was grown in Sabourand media. All cultures were 
cultivated in a shaking incubator at 37 °C for 24 h overnight prior to use. Mueller hinton agar (MHA) was pre-
pared by dissolving 38 g in 1 litre of distilled water, boiling the mixture for 1 min, after cooling and autoclaving, 
the media was poured into petri dishes. The plates were left to dry and subsequently stored at 37 °C. All microbial 
cultures were adjusted to 0.5 McFarland’s standard 1.5 × 108 CFU/ml and 4 × 106 CFU/ml of each organism used 
in experiments. Each microbe was swabbed evenly onto plates containing MHA. For sample addition, 100 µL of 
ACV at varying concentrations was added to the wells which were punched into the agar. The plates were then 
incubated at 37 °C for 24 h. Zones of inhibition surrounding samples were identified, photographed and measured 
in mm40. Experiments were repeated at least 5 times.
Ethical Approval and Informed Consent. All experimental protocols were approved by the Middlesex 
University Natural Sciences Ethics Committee number 2323. Further the methods were carried out in accordance 
to the relevant guidelines and regulations. Informed consent was received when applicable.
Human mononuclear cell isolation procedure from whole peripheral blood. Human leucocyte 
rich cones and serum were obtained from volunteer donors collected from NHS Cord blood and transplant bank 
at Colindale, London and treated as described previously41. Briefly the cones were washed with phosphate buffer 
saline to harvest the leucocyte rich cells. These were then spun on histopaque density gradient at 1200 RPM for 
20 min. Monocytes were purified using the CD14 positive mononuclear portion which was isolated according to 
manufacturer’s instruction provided with the pan monocyte isolation kit. Cells washed with HANKS balanced 
solution, counted and cultured into 24 well plates at 4 × 105 cells per mL. Cells were allowed to adhere for an hour 
at after which non-adherent cells were washed away and full media replenished with Dulbecco’s media containing 
10% human serum. Monocytes were determined using light microscopy and flow cytometry phenotypic analysis 
of differentiation markers as described previously using CD1441. Freshly isolated monocytes were cultured with 
varying concentrations of ACV and either C. albicans, E. coli or S. aureus at counts of 4 × 106 CFU/ml respectively 
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for 24 h at 37 °C and 5% CO2 after which supernatants were collected and analysed for TNF-α or IL-6 secretion 
using ELISA kits following manufacturer’s protocols.
Monocyte phagocytic capacity measurement by flow cytometry. Isolated human mononuclear 
cells were cultured at 4 × 105/mL in 24 well plates over a period of two days after which they were incubated with 
microbes (4 × 106 CFU/ml) for 4 h at 37 °C and 5 CO2. Cells were then scraped replenished in ice cold PBS con-
taining 1 mM EDTA, washed and removed from plates. The resultant pellets were fixed in 400 µL of 4% paraform-
aldehyde and analysed using a FACS Calibur flow cytometer (Beckton Dickinson Immunocytometry Systems, 
UK and Cell Quest software).
Preparation of microbial tryptic digests for mass spectroscopy analysis. An aliquot of microbial 
suspension was collected and treated over 24 h with 1/100 ACV, washed with PBS, resuspended in PBS and then 
treated with 1 mL of ice-cold acetone. The bacterial cells were harvested after centrifugation 13,000 g for 5 min. 
The pellet was dried and then reconstituted in 50 mM ammonium bicarbonate. Cells were lysed using a Soniprep 
150 Plus (MSE, U.K.) for 10 s with the amplitude set at 13. Subsequently proteins were denatured and reduced 
with 3 μL of 100 mM dithiothreitol in 50 mM ammonium bicarbonate at 95 °C for 5 min followed by alkylation 
with 6 μL of 100 mM iodoacetamide in the dark at room temperature for 20 min. Proteins were then digested with 
2 μL of trypsin (0.1 μg/μL dissolved in 50 mM ammonium bicarbonate) at 37 °C for 3 h. A further 2 μL of trypsin 
was added to the sample and the mixture was incubated at 37 °C for an additional 2 h. The samples were diluted in 
150 µL 50 mM ammonium bicarbonate and passed through Mini-Uni Prep filter devices.
Liquid Chromatography-Electrospray Ionisation Tandem Mass Spectrometry. The tryptic pep-
tides were analysed using a Shimadzu Prominence HPLC system hyphenated to an electrospray ionisation hybrid 
ion-trap time-of-flight (IT-TOF) mass spectrometer (Shimadzu, U.K.) operated in tandem mass spectrometry 
mode. Peptides were separated using an Ascentis Express 150 × 2.1 mm, 2.7 µm C18 column (Sigma-Aldrich, 
Poole, U.K.) using a flow rate of 0.21 mL/min. The column oven temperature was set to 40 °C. Data was acquired 
and processed using LabSolutions®software (version 3.50.348, Shimadzu, UK). A linear gradient elution profile 
composed of ‘A’−0.1% formic acid in water and ‘B’- 0.1% formic acid in acetonitrile was used. The gradient 
profile was 0–40% B, 70 min; 40–90% B, 1 min; maintained at 90% B, for 3 min; 90–0% B, 1 min; and 15 min 
re-equilibration at 0% B. An injection volume of 40 µL was used. Samples were kept in the auto sampler set to 
4 °C. Mass spectrometry analysis was performed in MS/MS mode using positive ions electrospray. The precursors’ 
acquisition range was set to 400–1,800 m/z while the fragments acquisition range was set to 200–1,500 m/z. For 
both precursors and fragments the ion accumulation time was set to 30 msec. The other instrument conditions 
were set as follows: detector voltage 1.6 kV, CID energy 70%, nebulising gas flow 1.5 L/min, CDL temperature 
200 °C, heat block temperature 200 °C, interface voltage 4.5 V, detector voltage 2 kV. The data acquisition was 
performed in a 37.5 min interval.
LC-MS/MS Data Processing. MS/MS data were extracted from the resulting instrument files using Mascot 
Distiller software (version 2.5.1.0, Matrix Science, London, UK). For precursors peak picking the following 
parameters were used: correlation threshold – 0.7, minimum signal to noise ratio – 5, minimum peak m/z – 50, 
maximum peak m/z – 100,000, minimum peak width – 0.02 Da, expected peak width – 0.2 Da, maximum peak 
width – 2 Da. The MS/MS ion list was searched using Mascot search engine against all entries in Swiss-Prot data-
base (2016_2). For database search the following parameters were used: two missed cleavages, carbamidometh-
ylation of cysteine (as fixed modification) and oxidation of methionine (as variable modification). The tolerance 
for precursor peptides was set to 10 ppm and for fragments to 0.3 Da. Peptide charges used for peak picking was 
+2, +3 and +4.
Statistical analysis. All experimental results are expressed as the mean ± standard deviation (SD). Statistical 
analyses was carried out using one way ANOVA or students t-test, outcomes were considered significant where 
p < 0.05 (when comparing apple cider vinegar treated microbes to the untreated groups in all experiments). All 
experiments were repeated at least 3–5 times. Analysis was carried out using Excel software version 2016.
Data availability. The datasets generated and analyzed during the current study reside with the correspond-
ing author and can be made available upon request.
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